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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
intravenous ramosetron 0.3 mg is effective in the prevention of postoperative nausea and 
vomiting (PONV) in women undergoing gynecologic surgery.  
 
STUDY DESIGN: Review of three English language primary research articles published later 
than 1995.  
 
DATA SOURCES: Randomized, double-blinded, controlled clinical trials comparing 
intravenous ramosetron to placebo or other control groups were identified using Ovid MEDLINE 
and Cochrane Library databases. 
 
OUTCOMES MEASURED: Measured outcomes include a complete response to the intervention 
within the first 24-48 hours, the incidence of postoperative nausea and vomiting, need for rescue 
antiemetic, severity of nausea, and patient satisfaction. 
 
RESULTS: All three RCTs analyzed found that intravenous ramosetron 0.3 mg administered 
during or immediately after surgery significantly decreased the incidence, compared to placebo, 
of patients experiencing any PONV. This effect was found to be particularly strong in the earliest 
postoperative period in all studies. In all three studies, ramosetron also significantly reduced the 
severity of nausea and increased patient satisfaction compared to placebo.  Two out of the three 
studies showed that ramosetron reduced the need for rescue treatment of PONV in the 
postoperative period compared to placebo. Adverse effects were limited to drowsiness, dizziness, 
and headache and there were no significant difference in incidence between any groups in any of 
the studies.  
 
CONCLUSION: PONV is a significant source of distress for women undergoing gynecologic 
surgery. The studies analyzed in this review are concordant in their finding that ramosetron, a 
highly selective 5-HT3 antagonist, is a safe and effective option for completely preventing or 
reducing the severity of this troubling postoperative complication. The effectiveness of 
ramosetron in these studies is complemented by its availability as a less-expensive oral 
disintegrating tablet which may offset criticism of the high cost of currently available 5-HT3 
antagonists. Future studies are needed to apply these findings to additional surgical populations.  
 
KEY WORDS: ramosetron, postoperative nausea and vomiting, gynecologic surgery 
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INTRODUCTION 
Postoperative nausea and vomiting (PONV) is a common and distressing complication of 
general anesthesia and surgery with a particularly high incidence in gynecologic surgery.1 The 
serotonin 5-HT3 receptor is highly specific for nausea and vomiting, and antagonists demonstrate 
potent antiemetic effects in PONV as well as chemotherapy- and radiation-induced nausea and 
vomiting.2-4 Ramosetron is a highly selective 5-HT3 antagonist that demonstrates a greater 
affinity for, and slower dissociation from, the 5-HT3 receptor than other drugs in this class,  
suggesting that it may provide longer-lasting antiemetic effects with fewer side effects.5 
The incidence of PONV in all surgical patients is approximately 25-30%, but can rise to 
75% in high-risk patients undergoing gynecologic surgery.6,7 Hysterectomy is the second most 
common surgery performed in women, at 600,000 procedures per year.  At a minimum incidence 
of 25%, PONV occurs in at least 150,000 cases per year for hysterectomy alone.8 
While PONV may be considered an inconvenience by some clinicians, it takes on greater 
significance when potential impacts on complications and patient care are considered. Prolonged 
PONV may lead to electrolyte imbalances, dehydration, aspiration of gastric contents, Mallory-
Weiss tears, esophageal rupture, wound dehiscence, and hematomas.2,7   Prevention of these 
events by preventing or reducing PONV reduces costs by helping to maintain the current 
emphasis on surgical care in the ambulatory setting. In one study, treating PONV with a placebo 
resulted in costs 100X greater than treating with a generic antiemetic.9 Approximately 0.18% of 
surgical patients experience intractable PONV which may lead to extended PACU stays or 
hospital admission.10 Each incidence of emesis may delay PACU discharge by 20 minutes, 
requiring significant nursing costs,11 and each day of hospital admission in the US costs an 
average of $1053.12 PONV will also likely become a challenge for a growing number of 
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physician assistants as employment opportunities in the surgical specialties or as hospitalists 
continue to expand.13  
 PONV is difficult to predict due to its multifactorial etiology. Patient-related risk factors 
include younger age, female gender, obesity, history of motion sickness, anxiety, nonsmoking, 
and gastroparesis. Operative variables include type, site, and duration of surgery.2,7  PONV is 
more commonly experienced with longer procedures and those involving laparoscopy, dilation 
and curettage of the uterus, knee arthroscopy, head and neck surgery, and gastrointestinal 
surgery.7 Anesthesia-related risk factors include postoperative pain, use of opioids in pain 
management, use of nitrous oxide in anesthesia, extended preoperative fasting, and absence of 
nasogastric suction.2  
Current guidelines recommend that PONV prophylaxis should be reserved for patients 
with a high risk. Treating low risk patients results in lack of benefit, unnecessary suffering of 
side effects, and increased costs.8 Four key indicators for high PONV risk include female gender, 
nonsmoking, history of PONV, and opioid use.6  If PONV risk warrants treatment, selective 
serotonin 5-HT3 receptor antagonists given at the conclusion of surgery are the current first-line 
therapy despite their high cost due to their efficacy and low side-effect profile. Droperidol, an 
antidopaminergic agent that is as effective as ondansetron in preventing PONV, was formerly the 
gold standard therapy but has been supplanted by 5-HT3 antagonists due to a “black box” 
warning imposed by the FDA on droperidol for possible induction of QT prolongation and 
torsades de pointes.8 Low-dose dexamethasone administered intravenously prior to surgery is 
effective at preventing PONV, but has not been studied systematically. Use of older antiemetics 
such as dimenhydrinate, ephedrine, prochlorperazine, promethazine and scopolamine has 
declined due to side effects including sedation, dizziness, and xerostomia.8 
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In summary, in patients at low risk for PONV, prophylaxis with older and less expensive 
antiemetics is recommended in order to prevent unnecessarily high costs.  Patients with a higher 
risk for PONV, such as those undergoing gynecologic surgery, warrant more effective and longer 
lasting prophylaxis to reduce additional PACU care and hospital admission.14 If ramosetron 
proves to be effective in the context of gynecologic surgery, it is also available as a less 
expensive oral disintegrating tablet, potentially offsetting criticism of the high cost of the 
intravenous formulation.15 
OBJECTIVE: 
The objective of this selective EBM review is to determine whether or not intravenous 
ramosetron 0.3 mg is effective in the prevention of PONV in women undergoing gynecologic 
surgery. 
METHODS: 
 The three studies selected for this review were prospective, randomized, double-blind, 
placebo-controlled controlled trials. All study populations were composed of adult women 
undergoing major gynecologic surgery and interventions included intravenous ramosetron 0.3 
mg administered at some point between induction of anesthesia and completion of surgery. In all 
studies, placebo infusion was used as a control and outcomes included complete response (i.e. no 
PONV) within the first 24-48 hours, incidence of PONV, need for rescue, severity of nausea, and 
patient satisfaction. All outcomes were patient-oriented evidence that matters (POEMS).   
A literature search was performed using Ovid Medline and the Cochrane Database of 
Systematic Reviews to identify randomized controlled trials (RCTs) using the keywords 
“ramosetron”, “nausea”, “vomiting”, and “postoperative.” Included search results were RCTs 
that were published after December 31, 1995 with study design and POEM outcomes that 
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answered the proposed question. Excluded studies were those published on or before December 
31, 1995, that were not RCTs, that studied women younger than 18 years old, or that studied 
non-gynecologic surgeries.  Articles selected for analysis were published after 1999 in English 
language, peer-reviewed journals. Studies were selected based on their study design, relevance to 
the question asked, and importance of outcomes to patients. Statistical analysis in the selected 
articles was limited to calculation of P-values. Table 1 lists the demographics and characteristics 
of patients in the included studies.  
In all selected studies, trained nurses were blinded to study groups and assessed patients 
at regular intervals to record all episodes of PONV in the PACU or general ward for the first 24 
to 48 hours.  This data was used to derive the measured outcomes of complete response, 
incidence of nausea and vomiting, and the need for rescue. Fujii et al divided the observation 
period into three time intervals: 0-1 hours, 1-24 hours, and 24-48 hours post-procedure. Lee et al 
used two intervals of 0-1 hours and 1-24 hours post-procedure. Kim et al used two intervals of 0-
6 hours and 6-24 hours post-procedure.  
Severity of nausea was rated by patients at each assessment using numeric visual 
analogue scales that ranged from from 0 (no nausea) to 10 or 100 (most severe nausea) or by 
modified Rhodes index questionnaire for nausea, retching and vomiting.16-18 Patient satisfaction 
was rated at the end of the studies using a linear scale ranging from 0 (complete dissatisfaction) 
to 10 (complete satisfaction)16,17 or three-point scale (satisfied, neutral, or dissatisfied).18  
RESULTS: 
Although patient characteristics and inclusion/exclusion criteria of the selected studies 
were not identical, Table 1 demonstrates that the patient populations were similar overall.   
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Table 1: Demographics and characteristics of patients in selected studies 
Study Type # pts Age Inclusion criteria Exclusion criteria W/D Interventions 
 
 
Fujii16, 
2000 
RCT 120 21-63 Healthy 21-63 year 
old females; 
Undergoing major 
gynecologic 
surgery;  
ASA physical 
status I/II  
GI disease;  
Hx of motion 
sickness and/or  
PONV;  
Antiemetic within 24 
hrs prior to surgery 
0 IV ramosetron at 
0.15 mg, 0.3 mg, 
and 0.6 mg at 
completion of 
surgery 
 
 
 
Kim18, 
2009 
RCT 162 21-71 Healthy 21-70 year 
old female 
undergoing elective 
gynecologic 
surgery under 
general anesthesia 
Pregnancy;   
Weight > 30% above 
ideal body weight;  
Vomiting or retching 
within 24 hrs before 
surgery;  
Antiemetic, steroids, 
or psychoactive 
meds within 24 
hours before surgery; 
Respiratory, CV, 
renal, hepatic, 
endocrine, GI, or 
neuro disease 
0 IV ramosetron 0.3 
mg or 
ondansetron 8 mg 
30 min prior to  
completion of 
surgery 
 
 
Lee17,  
2009  
RCT 120 18-60 Healthy 18-60 year 
old females 
undergoing major 
gynecologic 
surgery 
ASA physical 
status I/II 
GI disease;  
Hx of motion 
sickness or previous 
PONV;  
Currently 
menstruating;  
Antiemetic within 24 
hrs before surgery 
0 IV ramosetron 0.3 
mg immediately 
after anesthesia 
induction;  
Oral ramosetron 
0.1 mg 
administered 1 hr 
prior to surgery 
 
Table 2 shows the primary outcomes and resulting statistical analysis from the selected 
studies. In Fujii et al, a complete response was achieved with ramosetron in the 0-3 hour interval 
in 87% of patients compared to 40% with placebo. The relative benefit increase (RBI) and 
absolute benefit increase (ABI) were calculated to be 118% and 47%, respectively.  The number 
needed to treat (NNT) was calculated to be 2.  In the 3-24 hour interval, complete response was 
achieved in 87% compared to 43% with placebo. This effect was calculated to have an RBI of 
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102%, an ABI of 42%, and an NNT of 2. In the 24-48 hour interval, complete response was 
achieved in 90% of patients with ramosetron compared to 50% for placebo. This effect was 
calculated to have an RBI of 80%, ABI of 40%, and an NNT of 3.  For all of the above 
comparisons, P = 0.001  
Table 2   Primary outcome data from selected studies. Data reported as number of patients (%) 
Complete response = No PONV;  Interval = hours observed after anesthesia ;   
RBI= relative benefit increase;  RRR= relative risk reduction ; ABI=absolute benefit 
increase;  ARR= absolute risk reduction;  NNT= number needed to treat 
 
 
Primary 
Outcome 
Interval 
 
Placebo Ramosetron 
 
P* RBI/ 
RRR 
ABI/ 
ARR 
NNT 
0-3 12 (40%) 26 (87%) 0.001 118% 47% 2 
3-24 13 (43%) 26 (87%) 0.001 102% 44% 2 Fujii et al (2000) 
 
Complete  
response 
(No PONV) 
 
24-48 15 (50%) 27 (90%) 0.001 80% 40% 3 
0-1 26 (65%) 36 (90%) 0.014 38% 25% 4 Lee et al 
(2009) 
Complete 
response 
(No PONV) 
 
1-24 27 (67.5%) 35 (87.5%) 0.059 30% 20% 5 
Kim et al 
(2009) 
Incidence of  
any PONV 0-24 37 (69%) 27 (50%) <0.05 28%
†
 19%‡ 4 
*P value < 0.05 is statistically significant 
† 
 Reported as relative risk reduction  
‡
  Reported as absolute risk reduction 
 
In Lee et al, a complete response in the 0-1 hour interval was achieved in 90% of patients 
compared to 65% with placebo. The RBI was calculated to be 38%, ABI was calculated to be 
25%, and NNT was calculated to be 4, with a P value of 0.014. In the 1-24 hour interval, 
complete response was achieved in 87.5% compared to 67.5% with placebo with an RBI of 30% 
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and ABI of 20%.  For this less impressive effect, NNT was calculated to be 5.  These findings 
were deemed not statistically significant with a calculated P value of 0.059. 
In Kim et al, the incidence of nausea and/or vomiting was 50% in the ramosetron arm 
compared to 69% in the placebo arm in the combined 0-6 hour and 6-24 hour periods. Since the 
primary outcome was incidence of an undesirable effect instead of the incidence of a desirable 
effect, relative risk reduction (RRR) was calculated instead of benefit increase. For this effect, 
RRR was 28%, ARR was 19%, and NNT was 4. The comparison was found to be statistically 
significant with a calculated P value < 0.05.  
Table 3 shows the secondary outcomes and resulting statistical analysis from the selected 
studies. Secondary outcomes in Fujii et al included incidence of nausea and vomiting, need for 
rescue, severity of nausea, and patient satisfaction. While the incidence of both nausea and 
vomiting was reduced in the ramosetron arm in all three time intervals of Fujii et al, this effect 
reached statistical significance only for the incidence of nausea during the initial 0-3 hour 
interval (P = 0.041).  While rescue was required in 40%, 33%, and 27% of patients given 
placebo in the 0-3, 3-24, and 24-48 hour intervals, respectively, no patients given ramosetron 
required rescue at any time during the study (P = 0.001 – 0.004).  Again, this effect was most 
pronounced in the 0-3 hour interval with a calculated RRR of 67%, ARR of 40%, and NNT of 3.  
Values for severity of nausea and patient satisfaction were reported as ordinal data and 
not dichotomized for analysis in this review, but improvements in these outcomes in the 
ramosetron arm were noted in all time intervals and deemed to be statistically significant with P 
values ranging from 0.002 to 0.03.  
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Table 3   Secondary outcomes data from selected studies. Interval = hours observed after 
anesthesia;  Rescue = need for rescue antiemetic medication  
Data reported as number of patients (%) and mean 
 
 Interval Outcome Placebo Ramosetron P* RRR ARR NNT 
0-3 
 
 
Nausea 
Vomiting 
Rescue 
Severity† 
Satisfaction 
9 (30%) 
8 (27%) 
12 (40%) 
0 
2.5 
2 (7%) 
2 (7%) 
0 (0%) 
0 
8.5 
0.041 
0.079 
0.001 
0.002 
0.005 
33% 
27% 
67% 
-- 
-- 
23% 
20% 
40% 
-- 
-- 
4 
5 
3 
-- 
-- 
3-24 
 
Nausea 
Vomiting 
Rescue 
Severity† 
Satisfaction 
8 (27%) 
8 (27%) 
10 (33%) 
0 
2.5 
3 (10%) 
2 (7%) 
0 (0%) 
0 
8.5 
0.181 
0.079 
0.001 
0.03 
0.006 
23% 
27% 
49% 
-- 
-- 
17% 
20% 
33% 
-- 
-- 
6 
5 
3 
-- 
-- 
 
 
 
 
 
 
Fujii et al 
(2000) 
24-48 
 
Nausea 
Vomiting 
Rescue 
Severity† 
Satisfaction 
7 (23%) 
7 (23%) 
8 (27%) 
0 
3.5 
2 (7%) 
1 (3%) 
0 (0%) 
0 
8.5 
0.145 
0.052 
0.004 
0.022 
0.009 
21% 
26% 
37% 
-- 
-- 
16% 
20% 
27% 
-- 
-- 
6 
5 
4 
-- 
-- 
0-1 
 
Nausea 
Vomiting 
Rescue 
Severity‡ 
13 (32.5%) 
2 (5%) 
3 (7.5%) 
3.0 
4 (10%) 
1 (2.5%) 
1 (2.5%) 
0.7 
0.027 
1.00 
0.615 
0.013 
33% 
3% 
5% 
-- 
22.5% 
2.5% 
5% 
-- 
4 
40 
20 
-- 
 
 
 
Lee et al 
(2009) 1-24 Nausea 
Vomiting 
Rescue 
Severity‡ 
12 (30%) 
3 (7.5%) 
4 (10%) 
3.6 
5 (12.5%) 
1 (2.5%) 
1 (2.5%) 
1.1 
0.099 
0.615 
1.00 
0.041 
25% 
5% 
8% 
-- 
17.5% 
5% 
7.5% 
-- 
6 
20 
13 
-- 
Kim et al 
(2009) 
0-24 
 
Rescue 
Severity§ 
22 (41%) 
48 
8 (15%) 
28 
<0.05 
<0.05 
44% 
-- 
26% 
-- 
4 
-- 
P < 0.05 is statistically significant   † Severity based on a 0-10 VAS   ‡ Severity based 
on score of Modified Rhodes index of nausea, vomiting, and retching    
§
 Severity based on a 0-100 VAS 
 
In Lee et al, the incidences of nausea, vomiting, and rescue were reduced in the patients 
given ramosetron in both the 0-1 and 1-24 hour intervals, but a pronounced treatment effect was 
only seen for the incidence of nausea in the 0-1 hour interval, with a calculated P value of 0.027, 
RRR of 33%, ARR of 22.5%, and NNT of 4. All other comparisons regarding incidence of 
nausea, vomiting or rescue were not found to be statistically significant. Severity of nausea 
measured by Modified Rhodes index score was significantly reduced in both the 0-1 hour and 1-
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24 hour intervals by a mean 2.2 (P = 0.013) and 2.5 points (P = 0.041), respectively. Patient 
satisfaction was also increased by a mean of 1.5 on a linear numerical scale from 1-10 in the 
ramosetron arm (P < 0.001) 
In Kim et al, the incidence of rescue was 22% in the ramosetron arm versus 41% in the 
placebo arm. This statistically significant (P < 0.05) treatment effect had a RRR of 44%, ARR of 
26%, with an NNT of 4.  Patient satisfaction was reported as the number of patients in each study 
arm that were satisfied with the anesthetic experience, and was significantly higher with 
ramosetron, at 85%, versus those receiving placebo, at 69%.  This effect had a calculated RBI of 
23%, ABI of 16%, an NNT of 6, and was deemed statistically significant with a P value < 0.05. 
As in the other studies, severity of nausea was reported as ordinal data and not dichotomized for 
further analysis. However, ramosetron produced a mean 20 point reduction on a 100-point visual 
analogue scale, an effect that was found to be statistically significant with a P value of < 0.05. 
Headache, dizziness, and drowsiness were the most common adverse events recorded in 
the studies. Since there were no significant differences in the incidences of any adverse events 
among treatment groups in any study, no relative risk increase (RRI), absolute risk increase 
(ARI), or number needed to harm (NNH) analysis was performed.  
DISCUSSION:  
 
 The RCTs included in this review show notable concordance in both study design and 
results. A considerable limitation in studies of this type, however, lies in quantifying a response 
as multifactorial and subjective as PONV. Although inclusion criteria for all of the studies were 
similar, Kim et al used additional exclusion criteria that could be considered risk factors for 
PONV. Fujii et al and Lee et al may have included patients with these additional factors, leading 
to higher PONV risk in their study patients. In terms of study methods, Fujii et al administered 
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ramosetron at the completion of surgery, Kim et al administered the drug during surgery, and 
Lee et al administered the drug immediately after anesthesia induction. These differences may 
have skewed efficacy results, particularly in the early time intervals of the studies. All three 
studies also used different medication regimens to manage postoperative pain. These 
discrepancies could certainly impact the outcomes assessed in the studies.  
While the primary outcomes such as complete response and incidence of nausea/vomiting 
as measured by trained nurses may be considered very reliable, patient-derived data on need for 
rescue, overall satisfaction, and severity of nausea and vomiting may be skewed by several 
factors. Recovery from general anesthesia is a variable process that may render patients confused 
and unable to reliably quantify or qualify their level of discomfort.1,2 The need for rescue is also 
a subjective decision point that is ultimately based on patients’ individual threshold for 
discomfort. Since all studies were performed in Japan, the possibility of an ethnic or cultural bias 
in reporting the incidence and severity of nausea and vomiting cannot be ruled out.   
Interestingly, the mean values for severity of nausea in Fujii et al in all time intervals and 
treatment groups are 0, even though P values between ramosetron and placebo were calculated to 
be statistically significant (Table 3). This apparent discrepancy is not explained in the article and 
may represent a publication error.  
 The studies analyzed in this review did not emphasize adverse events and found no 
statistically significant occurrences in any study groups. Although ramosetron is a member of a 
well-studied drug class with an established safety record, it is only available in Japan and 
Southeast Asia as a treatment for diarrhea-predominant irritable bowel syndrome.  Since most 
studies on ramosetron have been performed in Asian patients, one must consider the possibility 
of increased safety in these populations due to pharmacogenetic variables. 
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CONCLUSION :  
 Ramosetron administered intravenously at a dosage of 0.3 mg either during or 
immediately following gynecologic surgery was shown to be effective in the prevention of 
PONV. This analysis suggests that ramosetron significantly increases the likelihood of 
eliminating any PONV when compared to placebo treatment in the first 48 hours after surgery, 
but that the treatment effects are more prominent in the early postoperative phase. For patients in 
whom ramosetron did not completely prevent PONV, the need for rescue therapy was 
significantly reduced compared to those who received placebo. The inherent difficulty of 
measuring a subjective and multifactorial event such as PONV warrants further study on this 
topic.  While pain management is required in any perioperative study, future investigations 
should minimize the use of opioids in pain control due to emesis-related side effects. Studies 
should also include more ethnically heterogenous patients to minimize potential 
pharmacogenetic effects and cultural bias in reporting the incidence and severity of nausea.  
The prospect of PONV weighs heavily on the minds of patients prior to surgery. As an 
increasing number of physician assistants assume work in surgical specialties, perioperative 
patient management will become an ever-increasing responsibility. Studies on prophylaxis of 
PONV with ramosetron should be expanded to other nations, patient populations, and surgical 
procedures to demonstrate whether or not ramosetron represents yet another effective option for 
physician assistants to dramatically improve the well-being of patients in the postoperative 
period.  
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